Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095931 | 0.95 | NAPEPLD (0.41) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL24378422 | 0.89 | KDM4E (0.42) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL23665928 | 0.88 | KDM4E (0.49) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL23649042 | 0.88 | KDM4E (0.43) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL24378574 | 0.86 | KDM4E (0.40) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL23665925 | 0.85 | NAPEPLD (0.46) | NAPEPLD | |
| SCHEMBL23665951 | 0.85 | KDM4E (0.41) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL23649034 | 0.84 | KDM4E (0.43) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL30079848 | 0.84 | KDM4E (0.43) | NAPEPLDKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL23665929 | 0.84 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | Verge Analytics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022261069-A1 | METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED PYRAZOLO-PYRIMIDINES | Verge Analytics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | PIKFYVE, PIP4K2B, PIP4K2C | NAPEPLD 3288/4885KDM4E 1122/4885HSD17B10 3596/4885 |
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | PIKFYVE, PIP4K2B, PIP4K2C | NAPEPLD 3288/4885KDM4E 1122/4885HSD17B10 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.